@article{3d707fe986d949baa3c0bebc9ad15216,
title = "Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery",
abstract = "The standard treatment for patients with locally advanced non-small-cell lung cancer (LA-NSCLC) is chemoradiotherapy (CRT), but surgical resection following induction CRT can extend overall survival in a select population. However, patients who survive longer are at risk of developing a second primary cancer (SPC). This is the first report to determine the incidence of SPC in survivors with LA-NSCLC after trimodal therapy. Between October 1997 and October 2013, 112 Stage III NSCLC patients underwent trimodal therapy in our hospital. The 5-year overall survival rate was 71.8%. SPC developed in 10 of the 112 patients 0.60-15.0 (median 5.49) years after initiating CRT. The observed incidence of SPC was 1.8 per 100 patient-years. Although trimodal therapy can prolong patient survival, the estimated incidence of SPC does not increase. A large prospective study with a longer follow-up time is required to determine the effects of trimodal therapy, including the development of SPC.",
keywords = "Cancer survivor, Chemoradiotherapy, Non-small-cell lung cancer, Second primary cancer, Surgical resection",
author = "Go Makimoto and Toshio Kubo and Isao Oze and Kadoaki Ohashi and Katsuyuki Hotta and Masahiro Tabata and Junichi Sou and Shinichi Toyooka and Kuniaki Katsui and Nagio Takigawa and Mitsune Tanimoto and Katsuyuki Kiura",
note = "Funding Information: Dr Hotta received personal fees from Nihon Kayaku, Sanofi-Aventis, during the conduct of the study; grants and personal fees from Merck, Chugai Pharmaceutical, Lilly, personal fees from AstraZeneca, Daiichi-Sankyo Pharmaceutical, Boehringer-Ingelheim, Taiho Pharmaceutical, Kyowa-Kirin, Ono, BMS, Novartis and Pfizer, outside the submitted work. Dr Takigawa received grants and personal fees from Eli Lilly Japan, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer Inc. Japan, Boehringer-Ingelheim, Ono Pharmaceutical, Kyowa Hakko Kirin, Nippon Kayaku Co. Ltd and Takeda Pharmaceutical Co. Ltd, outside the submitted work. Dr Kiura received grants and personal fees from Eli Lilly Japan, AstraZeneca, Chugai Pharmaceutical, Boehringer-Ingelheim, Kyowa Hakko Kirin, personal fees from Taiho Pharmaceutical, Pfizer Inc. Japan, grants from Ono Pharmaceutical, Astellas Pharmaceutical, outside the submitted work. Publisher Copyright: {\textcopyright} The Author(s) 2018. Published by Oxford University Press. All rights reserved.",
year = "2018",
month = mar,
day = "1",
doi = "10.1093/jjco/hyy003",
language = "English",
volume = "48",
pages = "287--290",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",
}
